XTX Topco Ltd Acquires Shares of 90,191 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

XTX Topco Ltd bought a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 90,191 shares of the company's stock, valued at approximately $565,000. XTX Topco Ltd owned approximately 0.13% of Phathom Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of America Corp DE raised its position in Phathom Pharmaceuticals by 60.4% during the fourth quarter. Bank of America Corp DE now owns 166,505 shares of the company's stock worth $1,352,000 after acquiring an additional 62,726 shares during the last quarter. Wells Fargo & Company MN raised its position in Phathom Pharmaceuticals by 41.3% during the fourth quarter. Wells Fargo & Company MN now owns 25,516 shares of the company's stock worth $207,000 after acquiring an additional 7,462 shares during the last quarter. ProShare Advisors LLC raised its position in Phathom Pharmaceuticals by 36.3% during the fourth quarter. ProShare Advisors LLC now owns 14,289 shares of the company's stock worth $116,000 after acquiring an additional 3,804 shares during the last quarter. Deutsche Bank AG raised its position in Phathom Pharmaceuticals by 49.4% during the fourth quarter. Deutsche Bank AG now owns 30,213 shares of the company's stock worth $245,000 after acquiring an additional 9,986 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Phathom Pharmaceuticals by 20.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 117,803 shares of the company's stock worth $957,000 after acquiring an additional 19,778 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Craig Hallum boosted their price objective on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, June 9th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Phathom Pharmaceuticals in a research report on Monday, June 9th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, June 6th. Finally, Guggenheim cut their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Phathom Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $17.50.

Phathom Pharmaceuticals Stock Up 3.6%

Shares of Phathom Pharmaceuticals stock traded up $0.34 during trading hours on Friday, hitting $9.74. The company's stock had a trading volume of 1,374,342 shares, compared to its average volume of 1,017,887. Phathom Pharmaceuticals, Inc. has a 1-year low of $2.21 and a 1-year high of $19.71. The business has a fifty day moving average of $8.81 and a 200 day moving average of $6.28. The company has a market capitalization of $679.95 million, a PE ratio of -2.06 and a beta of 0.45.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.